Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 1
1974 1
1975 2
1976 2
1977 3
1978 3
1979 1
1980 5
1983 4
1984 1
1985 2
1986 1
1987 2
1988 1
1989 2
1990 3
1991 3
1992 2
1993 2
1994 2
1995 1
1996 5
1997 2
1998 2
1999 1
2000 4
2002 3
2003 1
2004 2
2005 1
2006 5
2007 7
2008 1
2009 3
2010 2
2011 2
2012 1
2013 1
2014 1
2017 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

86 results
Results by year
Filters applied: . Clear all
Page 1
Issues in diisocyanate antibody testing.
Ott MG, Jolly AT, Burkert AL, Brown WE. Ott MG, et al. Crit Rev Toxicol. 2007;37(7):567-85. doi: 10.1080/10408440701419553. Crit Rev Toxicol. 2007. PMID: 17674212 Review.
Gene therapy for chronic granulomatous disease.
Stein S, Siler U, Ott MG, Seger R, Grez M. Stein S, et al. Among authors: ott mg. Curr Opin Mol Ther. 2006 Oct;8(5):415-22. Curr Opin Mol Ther. 2006. PMID: 17078383 Review.
Progress and prospects: gene therapy clinical trials (part 1).
Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH, Flotte TR, Gaspar HB, Grez M, Griesenbach U, Kaplitt MG, Ott MG, Seger R, Simons M, Thrasher AJ, Thrasher AZ, Ylä-Herttuala S. Alexander BL, et al. Among authors: ott mg. Gene Ther. 2007 Oct;14(20):1439-47. doi: 10.1038/sj.gt.3303001. Gene Ther. 2007. PMID: 17909539 Review.
Assessment of 1,3-butadiene epidemiology studies.
Ott MG. Ott MG. Environ Health Perspect. 1990 Jun;86:135-41. doi: 10.1289/ehp.9086135. Environ Health Perspect. 1990. PMID: 2205483 Free PMC article. Review.
Advances in the treatment of Chronic Granulomatous Disease by gene therapy.
Ott MG, Seger R, Stein S, Siler U, Hoelzer D, Grez M. Ott MG, et al. Curr Gene Ther. 2007 Jun;7(3):155-61. doi: 10.2174/156652307780859044. Curr Gene Ther. 2007. PMID: 17584034 Review.
An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.
Temam S, Spicer J, Farzaneh F, Soria JC, Oppenheim D, McGurk M, Hollebecque A, Sarini J, Hussain K, Soehrman Brossard S, Manenti L, Evers S, Delmar P, Di Scala L, Mancao C, Feuerhake F, Andries L, Ott MG, Passioukov A, Delord JP. Temam S, et al. Among authors: ott mg. Ann Oncol. 2017 Nov 1;28(11):2827-2835. doi: 10.1093/annonc/mdx489. Ann Oncol. 2017. PMID: 28950289 Free PMC article. Clinical Trial.
Respiratory effects of toluene diisocyanate in the workplace: a discussion of exposure-response relationships.
Ott MG, Diller WF, Jolly AT. Ott MG, et al. Crit Rev Toxicol. 2003;33(1):1-59. doi: 10.1080/713611031. Crit Rev Toxicol. 2003. PMID: 12585506 Review.
Occupational asthma, lung function decrement, and toluene diisocyanate (TDI) exposure: a critical review of exposure-response relationships.
Ott MG. Ott MG. Appl Occup Environ Hyg. 2002 Dec;17(12):891-901. doi: 10.1080/10473220290107093. Appl Occup Environ Hyg. 2002. PMID: 12495600 Review.
Screening for pre-diabetes and diabetes in the workplace.
Oberlinner C, Neumann SM, Ott MG, Zober A. Oberlinner C, et al. Among authors: ott mg. Occup Med (Lond). 2008 Jan;58(1):41-5. doi: 10.1093/occmed/kqm129. Epub 2007 Nov 19. Occup Med (Lond). 2008. PMID: 18025060
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma.
Delord JP, Tabernero J, García-Carbonero R, Cervantes A, Gomez-Roca C, Bergé Y, Capdevila J, Paz-Ares L, Roda D, Delmar P, Oppenheim D, Brossard SS, Farzaneh F, Manenti L, Passioukov A, Ott MG, Soria JC. Delord JP, et al. Among authors: ott mg. Eur J Cancer. 2014 Feb;50(3):496-505. doi: 10.1016/j.ejca.2013.10.015. Epub 2013 Nov 18. Eur J Cancer. 2014. PMID: 24262587 Clinical Trial.
86 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback